Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer

Prostate Cancer and Prostatic Diseases volume 12, pages 301–309 (2009)Cite this article

Abstract

We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mφ) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mφ/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mφ/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mφ/AdmIL-12-treated animals, more efficient trafficking of Mφ to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.

    Article  PubMed  Google Scholar 

  2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC . Natural history of progression after PSA elevation following radical prostatectomy. Jama 1999; 281: 1591–1597.

    Article  CAS  PubMed  Google Scholar 

  3. Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007; 110: 2628–2639.

    Article  CAS  PubMed  Google Scholar 

  4. Timme TL, Fujita N, Wang HY, Naruishi K, Kadmon D, Amato RJ et al. Cytokine Gene Therapy for Genitourinary Cancer. Humana Press: Totowa, 2006.

    Google Scholar 

  5. Miles BJ, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12: 1955–1967.

    Article  CAS  PubMed  Google Scholar 

  6. Ayala G, Wheeler TM, Shalev M, Thompson TC, Miles B, Aguilar-Cordova E et al. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol 2000; 31: 866–870.

    Article  CAS  PubMed  Google Scholar 

  7. Bingle L, Brown NJ, Lewis CE . The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254–265.

    Article  CAS  PubMed  Google Scholar 

  8. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC . Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60: 5857–5861.

    CAS  PubMed  Google Scholar 

  9. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 2003; 63: 7853–7860.

    CAS  PubMed  Google Scholar 

  10. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90: 2541–2548.

    CAS  PubMed  Google Scholar 

  11. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Therapy 1999; 6: 338–349.

    Article  CAS  PubMed  Google Scholar 

  12. Oz MC, Cosgrove III DM, Badduke BR, Hill JD, Flannery MR, Palumbo R et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. Ann Thorac Surg 2000; 69: 1376–1382.

    Article  CAS  PubMed  Google Scholar 

  13. Reuthebuch O, Lachat ML, Vogt P, Schurr U, Turina M . FloSeal: a new hemostyptic agent in peripheral vascular surgery. Vasa 2000; 29: 204–206.

    Article  CAS  PubMed  Google Scholar 

  14. Ellegala DB, Maartens NF, Laws Jr ER . Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: technical note. Neurosurgery 2002; 51: 513–515; discussion 515–516.

    Article  PubMed  Google Scholar 

  15. Ahlering TE, Eichel L, Chou D, Skarecky DW . Feasibility study for robotic radical prostatectomy cautery-free neurovascular bundle preservation. Urology 2005; 65: 994–997.

    Article  PubMed  Google Scholar 

  16. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL . Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995–2002.

    Article  CAS  PubMed  Google Scholar 

  17. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA et al. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995; 10: 869–879.

    CAS  PubMed  Google Scholar 

  18. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882–3885.

    CAS  PubMed  Google Scholar 

  19. Lee HM, Timme TL, Thompson TC . Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927–1933.

    CAS  PubMed  Google Scholar 

  20. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223–1230.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA

    K Tabata, M Watanabe, K Naruishi, K Edamura, T Satoh, G Yang, E Abdel Fattah, J Wang, A Goltsov, D Floryk, S D Soni, D Kadmon & T C Thompson

  2. Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA

    D Kadmon & T C Thompson

  3. Department of Radiology, Baylor College of Medicine, Houston, TX, USA

    T C Thompson

  4. Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA

    T C Thompson

Authors
  1. K Tabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Naruishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Edamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Abdel Fattah
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Goltsov
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Floryk
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S D Soni
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D Kadmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T C Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T C Thompson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tabata, K., Watanabe, M., Naruishi, K. et al. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis 12, 301–309 (2009). https://doi.org/10.1038/pcan.2008.57

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2008.57

Keywords

This article is cited by

Search

Advanced search

Quick links